Your browser doesn't support javascript.
loading
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.
Thomas, Alexandra; Routh, Eric D; Pullikuth, Ashok; Jin, Guangxu; Su, Jing; Chou, Jeff W; Hoadley, Katherine A; Print, Cristin; Knowlton, Nick; Black, Michael A; Demaria, Sandra; Wang, Ena; Bedognetti, Davide; Jones, Wendell D; Mehta, Gaurav A; Gatza, Michael L; Perou, Charles M; Page, David B; Triozzi, Pierre; Miller, Lance D.
Afiliação
  • Thomas A; Section of Hematology and Oncology, Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
  • Routh ED; Wake Forest Comprehensive Cancer Center, Winston-Salem, NC, USA.
  • Pullikuth A; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Jin G; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Su J; Wake Forest Comprehensive Cancer Center, Winston-Salem, NC, USA.
  • Chou JW; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Hoadley KA; Division of Radiologic Sciences and Center for Bioinformatics and Systems Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA.
  • Print C; Wake Forest Comprehensive Cancer Center, Winston-Salem, NC, USA.
  • Knowlton N; Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Black MA; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Demaria S; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Wang E; Department of Molecular Medicine and Pathology and Maurice Wilkins Institute, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Bedognetti D; Department of Molecular Medicine and Pathology and Maurice Wilkins Institute, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Jones WD; Department of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
  • Mehta GA; Department of Radiation Oncology and Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Gatza ML; Department of Tumor Biology, Immunology and Therapy, Division of Translational Medicine, Sidra Medical and Research Center, Doha, Qatar.
  • Perou CM; Department of Tumor Biology, Immunology and Therapy, Division of Translational Medicine, Sidra Medical and Research Center, Doha, Qatar.
  • Page DB; EA Genomics, Division of Q Solutions, Morrisville, NC.
  • Triozzi P; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Miller LD; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Oncoimmunology ; 7(10): e1490854, 2018.
Article em En | MEDLINE | ID: mdl-30386679
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article